GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that, effective February 13, 2012, Dr. Jorge Garces has joined GenMark as Senior Vice President, Research and Development. Dr. Garces joins the GenMark team with extensive diagnostics experience, including most recently serving as Chief Executive Officer and President of the Enigma Diagnostics US business. Prior to Enigma Diagnostics, Dr. Garces served as Vice President of R&D and Site Operations Manager at Hologic, Inc., where he managed the R&D, Clinical and Manufacturing business unit in Madison, WI, and led the development and submission to FDA for approval of their Cystic Fibrosis and HPV products. Additionally, Dr. Garces held the role of Senior Vice President of Research and Development at Third Wave Technologies Inc. and earlier in his career held positions at Genzyme Genetics and Athena Diagnostics, Inc. Dr. Garces earned his bachelor's degree in Biology from Brooklyn College and his doctorate in Cell and Molecular Biology from the City University of New York. He completed his post-doctoral training at the University of Massachusetts Medical School and received an MBA from the Kellogg Graduate School of Management. “We are delighted to welcome Jorge to the GenMark team,” said Hany Massarany, GenMark’s President and CEO. “He brings extensive technology expertise and diagnostics industry experience, which will be central to our continued focus on innovation and business growth. The addition of Jorge to the GenMark team will allow us to accelerate our product development initiatives, which are very focused on the expansion of our high value diagnostic testing menu and the development of our next generation sample to answer platform.” About GenMark Diagnostics, Inc. GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets three tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test. A Respiratory Viral Panel (RVP) has been submitted to the FDA for 510(k) clearance. A number of other tests, including HCV Genotyping and 2C19, versions of which are available for research use only, and KRAS, are in development for IVD use. For more information, visit www.genmarkdx.com. Safe Harbor Statement This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, the development and intended functionality of our products and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual performance, operating results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, our ability to successfully commercialize our products, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, ability to maintain gross margins, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.